Low
₹698.85
High
₹711.80
| Previous Close | ₹707.80 |
|---|---|
| Day's Range | ₹698.85 - ₹711.80 |
| Open | ₹710.10 |
| 52 Week Range | ₹545.50 - ₹832.40 |
| Volume | 76,588 |
| Market Cap | ₹0.01 |
| Previous Close | ₹707.10 |
|---|---|
| Day's Range | ₹698.90 - ₹712.90 |
| Open | ₹712.90 |
| 52 Week Range | ₹545.65 - ₹831.00 |
| Volume | 2,415 |
| Market Cap | ₹0.01 |
| Trade Value ( ₹ in Lacs) | 542.09 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 30.43 |
| TTM EPS (₹) | 23.02 |
| P/E Ratio | 31.41 |
| Book Value(₹) | 4.98 |
| PAT Margin (%) | 24.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 27.63 |
| Trade Value ( ₹ in Lacs) | 17.08 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.14 |
| Price/Earning (TTM) | 30.43 |
| TTM EPS (₹) | 23.02 |
| P/E Ratio | 31.41 |
| Book Value(₹) | 4.98 |
| PAT Margin (%) | 24.04 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 27.63 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1856.48 | 5703.4 |
| Expenses | N/A | N/A |
| PBT | 625.8 | 1656.9 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 467.83 | 1191.14 |
| Founded | 2008 |
|---|---|
| Managing Director | Saloni Satish Wagh |
| NSE Symbol | SUPRIYA |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,134.01 | 1,850.40 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,77,883.86 | 6,719.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,526.68 | 4,391.75 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,12,696.26 | 8,092.00 | 6,677.50 - 6,677.50 |
| Lupin Ltd. | 1,12,463.67 | 2,380.50 | 1,836.80 - 1,836.80 |
| Cipla Ltd. | 1,10,088.66 | 1,348.50 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,072.97 | 1,297.20 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,793.98 | 1,014.50 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 98,063.24 | 2,438.85 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,596.06 | 941.80 | 835.50 - 835.50 |
No Records Found
Further to its Letters dated February 04, 2026, February 09, 2026, and February 10, 2026, Supriya Lifescience has informed that the Transcript of the Earnings Call held on February 10, 2026, with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, is available on the Company's website at: https://www.supriyalifescience.com/ir-financial.php.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed copies of the newspaper advertisements pertaining to Notice to Shareholders with respect to, ‘Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26’. The advertisements were published in ‘Business Standard’ (English) and ‘Prajasakti’ (Telugu) on May 07, 2026.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Biocon has informed that it enclosed the presentation with respect to Q4 FY26 Earnings Call to be conducted on May 08, 2026. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Supriya Lifescience Ltd. is ₹707.80 as of 2026-05-08.
The market capitalisation of Supriya Lifescience Ltd. is ₹5,637.02 as of 2026-05-07.
The 1-year return of Supriya Lifescience Ltd. is 6.75% as of 2026-05-08.
The P/E ratio of Supriya Lifescience Ltd. is 31.41 as of 2026-05-08.
The 52-week high and low of Supriya Lifescience Ltd. are ₹832.40 and ₹545.50, respectively, as of 2026-05-08.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.